EUCTR2007-004729-16-IT进行中（未招募）不适用
A randomised, double-blind study to assess the efficacy and safety of prophylactis use of maribavir versus oral ganciclovir for the prevention of cytomegalovirus disease in recipients of orthotopic liver transplants - ND
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 348
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Be informed of the nature of the study and provide written informed consent before any study-specific procedures are performed.
- •2. Be ≥ 18 years of age.
- •3. Weigh ≥ 40 kg.
- •4. Be undergoing their first orthotopic liver transplantation (the transplanted graft may
- •be a deceased-donor whole organ, a deceased-donor split-liver graft, or live-donor graft).
- •5. Have negative pre-transplantation CMV serology and receive a liver from a donor with positive pre-transplantation CMV serology (i.e., donor positive / recipient negative [D+ R?]).
- •6. Have no detectable CMV infection post-transplant. This must be documented by CMV testing of blood using either CMV pp65 antigenemia assay, CMV DNA PCR,or other CMV DNA detection assay from a sample collected post-transplant. Results
- •from either the central laboratory or a local laboratory can be used for qualification.
- •7. Have the following findings as part of screening laboratory assessments (results from either the central laboratory or a local laboratory can be used for qualification: Absolute neutrophil count (ANC) ≥500/mm3 [0.5 x 109/L; Platelet count ≥25,000/mm3 [25 x 109/L]
- •8. Be randomized such that dosing with study drug can begin within 10 days posttransplant.
- •9. If female, be either postmenopausal, surgically sterile, or have a negative serum pregnancy test as part of screening laboratory assessments. Women of child bearing
- •potential also must agree to use an acceptable method of birth control (e.g., abstinence, IUD, or barrier method), as determined by the investigator, during the study drug administration period and for 3 months afterward. Hormonal contraceptives should not be used as the sole method of birth control. If male, must agree to use an acceptable method of birth control (e.g., abstinence or
- •barrier method), as determined by the investigator, during the study drug
- •administration period and for 3 months afterward.
- •10. Be able to swallow tablets and capsules
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Be undergoing multi-organ transplantation or have undergone prior organ transplantation (except skin, hair, or cornea).
- •2. Have known human immunodeficiency virus (HIV) infection (based on testing
- •performed during the transplant evaluation process or during screening for this study).
- •3. Have CMV-related organ disease within 6 months prior to the day of enrollment.
- •4. Be receiving any of the following therapies at the time of enrollment: ganciclovir, valganciclovir, foscarnet, cidofovir, acyclovir (>25 mg/kg IV per day, valacyclovir (>3 g p.o. per day, famciclovir (>1500 mg p.o. per day)NOTE: A subject may have received any of the above listed drugs prior to enrollment. If this is the case, these drugs must be discontinued by the time of enrollment; no minimum ?washout? period is required before commencement of dosing with study drugs.
- •5. Have received cytomegalovirus immune globulin within 30 days prior to the day of enrollment.
- •6. Be receiving therapy with phenytoin at the time of enrollment.
- •7. Have estimated creatinine clearance <10 mL/min or require dialysis at time of enrollment.
- •8. Have severe vomiting, diarrhea or other severe gastrointestinal illness within 24 hours prior to the time of enrollment that would preclude administration of oral medication.
- •9. Require mechanical ventilation or vasopressors for hemodynamic support at time of enrollment.
- •10. Be pregnant (as determined by β-hCG testing prior to initiation of study drug) or breastfeeding.
- •11. Have received any investigational antiviral agent or investigational
- •immunosuppressant agent within 30 days before the initiation of study drug.
- •12. Have received maribavir in a previous clinical trial.
- •13. Have any clinically significant medical or surgical condition (other than the underlying reason for transplantation) that in the investigator?s or sponsor?s
- •opinion would compromise the outcome of the study
研究者
相似试验
进行中（未招募）
1 期
Effect of testosterone in male patients on regular hemodialysisHypogonadal males undergoing hemodialysis (HD).EUCTR2011-005439-20-SEDept of Renal medicine40
已完成
不适用
Double-blind randomised study into the efficacy of codeine phosphate analgesia after cleft palate repair in infantsCleft palateISRCTN86816150Department of Health
进行中（未招募）
不适用
A randomised, double blind study to evaluate the safety and efficacy of the p38 kinase inhibitor, GW856553, in subjects with neuropathic pain from lumbosacral radiculopathyEUCTR2009-012836-33-SEGlaxoSmithKline Research & Development Limited142
进行中（未招募）
不适用
A randomised, double blind study to evaluate the safety and efficacy of the p38 kinase inhibitor, GW856553, in subjects with neuropathic pain from lumbosacral radiculopathyeuropathic pain from lumbosacral radiculopathyMedDRA version: 12.0Level: LLTClassification code 10037779Term: RadiculopathyEUCTR2009-012836-33-DEGlaxoSmithKline Research & Development Limited142
进行中（未招募）
1 期
A randomised, double blind study to evaluate the safety andefficacy of the p38 kinase inhibitor, GW856553, in subjects withneuropathic pain from peripheral nerve injury.Estudio aleatorizado, doble ciego para evaluar la seguridad y la eficacia de GW856553, un inhibidor de la quinasa p38, en sujetos con dolor neuropático por lesión de nervio periférico.europathic painMedDRA version: 9.1Level: LLTClassification code 10054095Term: Neuropathic painEUCTR2009-010091-17-ESGlaxoSmithKline Research & Development Limited